Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders

The Latest from Chimeron Bio

In the News

December 7, 2020

Chimeron Bio Appoints CEO of Evox Therapeutics and Former CSO of Moderna, Dr. Antonin de Fougerolles to Its Scientific Advisory Board

Chimeron Bio has announced the appointment of Dr. Antonin (Tony) de Fougerolles, CEO of Evox Therapeutics and former CSO of Moderna, to its Scientific Advisory Board.

From Our Blog

July 1, 2020

My Science, My Strongest Tool for Social Justice

The pharma and biotech community can help address not only unmet health needs, but also health inequities. Our role as scientists is critical right now.

Learn more about our COVID-19 Vaccine Program.

See what makes ChaESAR™ a robust anti-viral approach.

Read the Press Release